June 17, 2008
Lytix Reveals Further Details on First Cancer Candidate Oncopore at BIO2008
The Scandinavian-based drug development company Lytix Biopharma revealed more information on its lead anti-cancer molecule Oncopore at BIO 2008 in San Diego. The first of a novel class of drugs, Oncopore is based on an anti-cancer pharmacophore of lactoferrin and is the result of systematic QSAR work and extensive preclinical studies.
According to Lytix Biopharma CEO 0ystein Rekdal this is an important milestone for the company: "Oncopore is the company`s first oncology product for clinical development. We envisage it being used for the local treatment of solid tumours, potentially in combination with existing therapies. Oncopore is currently in preclinical development and has proven efficacy across a range of 40 tumour cell lines, including lines resistant to established chemotherapy. It also exhibits high selectivity compared to conventional chemotherapy. In vivo studies in syngeneic mice show the potential for a rapid induction of necrosis, immune-mediation and complete and stable tumour response. Clinical phase I/II will be initiated in 2009."
About Lytix Biopharma AS
The Scandinavian based company Lytix Biopharma commercialises world-class research in synthetic peptide therapeutics by its founding scientists working in the University Hospital and University of Troms0 in Norway. The initial pipeline includes micro-size synthetic antimicrobial peptides (SAMPs(TM)) for the treatment of multiresistant bacteria, fungal infections and cancer.
In addition to equity, the company and its research programme has received substantial grants from the Norwegian Research Council through its BIA and FUGE programmes. Lytix operates from state-of-the-art laboratories in the Troms0 Science Park with business development in Oslo. The development team has extensive experience of developing peptide based drugs, including preparation of peptides and peptidomimetics, synthesis of non-coded amino acids, medicinal chemistry, pharmacokinetics, QSAR and peptide drug design.